Yahoo Finance

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the following presentations related to emiltatug ledadotin (Emi-Le; XMT-1660), Mersana’s B7-H4-directed Dolasynthen ADC, will be given at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking place May 30-June 3, 2025 at McCormick Place, Chicago, IL:

Oral Presentation Details

• Title: Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin (Emi-Le), a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate

• Rapid Oral Session Title: Developmental Therapeutics

• Date and Time: Monday, June 2, 2025 from 8:00-9:30 a.m. CT

• Abstract Number: 3009

• Presenter: Erika Hamilton, M.D., Director Breast Cancer Research Program, Sarah Cannon Research Institute in Nashville, Tennessee
  

This presentation will include clinical data from dose escalation and backfill cohorts across tumor types from the ongoing Phase 1 clinical trial of Emi-Le.

Poster Presentation Details

• Title: Emiltatug Ledadotin (Emi-Le): A B7-H4-Directed Dolasynthen Antibody-Drug Conjugate (ADC) Being Investigated in Phase 1 Dose Expansion in Patients with Triple Negative Breast Cancer Who Received at Least One Prior Topoisomerase-1 Inhibitor ADC

• Poster Session Title: Breast Cancer - Metastatic

• Date and Time: Monday, June 2, 2025 from 9:00-12:00 p.m. CT

• Abstract Number: TPS1141

• Presenter: Hyo Han, M.D., H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
  

This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple negative breast cancer (TNBC) who have received one to four prior treatment lines, including at least one topoisomerase-1 inhibitor ADC.

Additionally, as previously announced, an oral presentation regarding Emi-Le will be given at the ESMO Breast Cancer 2025 Annual Congress in Munich, Germany on Thursday, May 15, 2025. This presentation will focus on TNBC clinical data from dose escalation and backfill cohorts from the Phase 1 clinical trial of Emi-Le.

About Emi-Le
Emi-Le is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary auristatin payload with controlled bystander effect. This candidate is being investigated in a Phase 1 dose escalation and expansion trial in patients with solid tumors, including breast, endometrial and ovarian cancers as well as adenoid cystic carcinoma type 1. In the initial clinical data that were reported as of a December 13, 2024 data cutoff, Emi-Le was observed to be generally well tolerated with differentiated safety and tolerability profile. Additionally, confirmed objective responses were observed across all enrolled tumor types, including in patients with triple negative breast cancer (TNBC) who had previously been treated with a topoisomerase-1 inhibitor (topo-1) ADC.